Other · developed by Immunocore
IMC-P115C is an agent studied in PRAME-positive cancers in HLA-A*02:01-positive patients. PRAME is the tumor antigen it is directed against.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07156136 | Phase 1 | PRAME Positive | Recruiting | IMCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerHLA-A*02:01-positivePRAME Positive
See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMCR catalysts and pipeline →